Poniard Pharmaceuticals Picoplatin for Treatment of Small Cell Lung Cancer

Sept 05, 2007 - Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) : it has been granted fast track designation by the U.S. Food and Drug Administration (FDA) for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer (SCLC)... Read the Poniard Pharmaceuticals' Press Release -

Pfizer Oncology, Advanced Non-Small Cell Lung Cancer

September 05, 2007 - Pfizer : initiation of a large, global Phase III clinical trial to evaluate the efficacy and safety of sunitinib malate, in combination with erlotinib, in previously treated patients with advanced non-small cell lung cancer (NSCLC)... Pfizer's Press Release -

A blog about Lung's Diseases

The aim of the Blog "LungPosition" is to share information found in life sciences companies websites which could be interesting to follow new medical devices, pharmaceuticals, treatments, clinical trials for lung's diseases.